Product image of Insulin Aspart Sanofi (Insulin Aspart) supplied by GNH India

Insulin Aspart Sanofi

Active Ingredient:
Insulin Aspart
Origin:
EU

Insulin Aspart Sanofi (Insulin Aspart)

Insulin Aspart, the active ingredient in Insulin Aspart Sanofi, is a rapid-acting insulin analog presented as an injection solution for subcutaneous use. It treats diabetes mellitus in both type 1 and type 2 patients.

GNH India supplies Insulin Aspart Sanofi as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Sanofi Winthrop Industrie

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Insulin Aspart is a rapid‑acting insulin analog used to manage blood glucose in diabetes mellitus.
  • Type 1 diabetes mellitus: improves post‑prandial glucose control and reduces hyperglycaemic episodes.
  • Type 2 diabetes mellitus: assists in achieving glycaemic targets when combined with oral antidiabetic agents.
  • Diabetic ketoacidosis (intensive therapy): provides rapid insulin action needed for metabolic stabilization.

How It Works

  • Insulin Aspart binds to insulin receptors on muscle, adipose and hepatic cells, triggering receptor autophosphorylation and downstream signaling that enhances glucose transporter (GLUT4) translocation. This accelerates cellular glucose uptake and suppresses hepatic gluconeogenesis, resulting in a rapid reduction of plasma glucose levels after injection.

Side Effects

Common Side Effects

  • Hypoglycaemia: low blood glucose levels, especially if meals are missed or dosing is excessive.
  • Injection‑site reactions: redness, swelling, or itching at the injection site.
  • Weight gain: modest increase due to improved glucose utilisation.
  • Lipodystrophy: localized changes in subcutaneous fat with repeated injections.
  • Mild nausea or gastrointestinal discomfort.

Serious or Rare Side Effects

  • Anaphylactic reaction: severe allergic response requiring immediate medical attention.
  • Severe hypoglycaemia leading to seizures or loss of consciousness.
  • Hypokalemia: low potassium levels, potentially precipitated by rapid glucose shifts.
  • Acute insulin resistance: unexpected poor glucose response despite appropriate dosing.

Precautions & Warnings

  • Insulin Aspart requires careful monitoring and individualized dosing.
  • Dose adjustment: modify dose based on blood glucose trends and carbohydrate intake.
  • Hypoglycaemia risk: educate patients on recognising and treating low blood glucose.
  • Renal impairment: monitor renal function as insulin clearance may be reduced.
  • Pregnancy and lactation: use only if benefits outweigh potential risks.
  • Drug interactions: avoid concomitant use with other rapid‑acting insulins without medical supervision.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Insulin Aspart may interact with several medicines that affect glucose metabolism.

Major Interactions (Avoid)

  • Other insulin products: concurrent use can cause severe hypoglycaemia.
  • Beta‑blockers: may mask hypoglycaemia symptoms, complicating detection.
  • Alcohol: enhances insulin’s glucose‑lowering effect, increasing hypoglycaemia risk.

Moderate Interactions (Monitor Closely)

  • Thiazolidinediones: additive glucose‑lowering effect, require dose adjustments.
  • Diuretics (especially thiazides): may raise blood glucose, necessitating closer monitoring.
  • ACE inhibitors or ARBs: can potentiate insulin’s effect in some patients, warranting glucose checks.

Frequently Asked Questions

Insulin Aspart Sanofi is a rapid‑acting insulin analog indicated for the management of blood glucose in adults with type 1 or type 2 diabetes mellitus. It is used to control post‑prandial glucose spikes and to provide flexible insulin coverage around meals.

Insulin Aspart mimics natural insulin by binding to insulin receptors on muscle, fat and liver cells. This activates intracellular pathways that promote glucose uptake into cells and suppress hepatic glucose production, leading to a rapid decline in circulating blood glucose after injection.

The dose of Insulin Aspart Sanofi is individualized. A qualified prescriber determines the amount, timing and frequency based on the patient’s blood‑glucose profile, carbohydrate intake, and overall treatment plan. Patients should follow the prescribing clinician’s instructions precisely.

Safety data for Insulin Aspart in pregnancy and lactation are limited. It may be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Decisions should be made by the treating obstetrician and endocrinologist.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and necessary import documentation.

Insulin Aspart has a similar onset of action (approximately 10‑20 minutes) and duration (3‑5 hours) to other rapid‑acting analogues such as insulin lispro and insulin glulisine. Its molecular modifications provide slightly faster absorption, which can improve post‑meal glucose control for some patients.

Insulin Aspart should be stored in a refrigerator at 2‑8 °C, protected from light, and never frozen. Once in use, the vial or pen may be kept at controlled room temperature (up to 30 °C) for a maximum of 28 days, after which any remaining product should be discarded.

Insulin Aspart is administered by subcutaneous injection using a sterile needle or an insulin pen. It is typically injected into the abdomen, thigh or upper arm, rotating sites with each dose to reduce the risk of lipodystrophy. The injection should be given within 5‑10 minutes before a meal.

The most serious risks include severe hypoglycaemia, which can lead to seizures, loss of consciousness or injury, and rare allergic reactions such as anaphylaxis. Patients should be educated on recognising early signs of low blood glucose and have rapid‑acting carbohydrate sources readily available.

Insulin Aspart is contraindicated in individuals with a known hypersensitivity to insulin Aspart or any of its excipients. It should also be avoided in patients with severe hypoglycaemia unresponsive to treatment, or in those for whom rapid‑acting insulin therapy is not appropriate without medical supervision.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Insulin Aspart

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT